These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12397201)

  • 21. Primary mediastinal large B-cell lymphoma.
    Ergul SM; Lal A; Afri L; Frei-Lahr D
    South Med J; 2002 Sep; 95(9):1005-7. PubMed ID: 12356098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma.
    Coiffier B
    Curr Hematol Rep; 2003 Jan; 2(1):23-9. PubMed ID: 12901151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular outcome prediction in diffuse large-B-cell lymphoma.
    Alizadeh AA; Gentles AJ; Lossos IS; Levy R
    N Engl J Med; 2009 Jun; 360(26):2794-5. PubMed ID: 19553658
    [No Abstract]   [Full Text] [Related]  

  • 24. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug resistance in diffuse large B-cell lymphoma.
    Wilson WH
    Semin Hematol; 2006 Oct; 43(4):230-9. PubMed ID: 17027657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited.
    Segal MR
    Biostatistics; 2006 Apr; 7(2):268-85. PubMed ID: 16284340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
    Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases.
    Lin P; Mansoor A; Bueso-Ramos C; Hao S; Lai R; Medeiros LJ
    Am J Clin Pathol; 2003 Aug; 120(2):246-53. PubMed ID: 12931555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is intestinal diffuse large b cell lymphoma a relatively benign disease?
    Daum S; Thiel E; Zeitz M
    Leuk Res; 2007 Mar; 31(3):287-9. PubMed ID: 17010434
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic factors in diffuse large B-cell lymphoma.
    Niitsu N
    Intern Med; 2006; 45(5):227-8. PubMed ID: 16595984
    [No Abstract]   [Full Text] [Related]  

  • 33. Fuzzy neural network applied to gene expression profiling for predicting the prognosis of diffuse large B-cell lymphoma.
    Ando T; Suguro M; Hanai T; Kobayashi T; Honda H; Seto M
    Jpn J Cancer Res; 2002 Nov; 93(11):1207-12. PubMed ID: 12460461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.
    Andreadis C; Gimotty PA; Wahl P; Hammond R; Houldsworth J; Schuster SJ; Rebbeck TR
    Blood; 2007 Apr; 109(8):3409-16. PubMed ID: 17179223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian profiling of molecular signatures to predict event times.
    Zhang D; Zhang M
    Theor Biol Med Model; 2007 Jan; 4():3. PubMed ID: 17239251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of PRDM1beta expression as a prognostic marker in diffuse large B-cell lymphomas.
    Tam W; Gomez M; Nie K
    Blood; 2008 Feb; 111(4):2488-9; author reply 2489-90. PubMed ID: 18263789
    [No Abstract]   [Full Text] [Related]  

  • 37. [The profiling era: towards innovative approaches for tailored therapy].
    Roulland S; Nadel B
    Med Sci (Paris); 2009; 25(6-7):553-5. PubMed ID: 19602345
    [No Abstract]   [Full Text] [Related]  

  • 38. Algorithmic fusion of gene expression profiling for diffuse large B-cell lymphoma outcome prediction.
    Zhu Q; Cui H; Cao K; Chan WC
    IEEE Trans Inf Technol Biomed; 2004 Jun; 8(2):79-88. PubMed ID: 15217252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic strategies to individualize supportive care.
    McLeod HL
    J Clin Oncol; 2002 Jun; 20(12):2765-7. PubMed ID: 12065551
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of Choi and Hans' algorithms by immunohistochemistry and quantitative reverse transcriptase-PCR - letter.
    Ballabio E; Chi J; Roncador G; Banham AH; Hatton CS; Lawrie CH
    Clin Cancer Res; 2010 Jul; 16(14):3805-6. PubMed ID: 20628029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.